Generic Name and Formulations:
Dornase alfa (recombinant human DNase) 1mg/mL; soln for inh; preservative-free.
Indications for PULMOZYME:
Management of cystic fibrosis in conjunction with standard therapies to improve pulmonary function.
Adults and Children:
<3months: not recommended. Use appropriate nebulizer. Do not dilute. >5yrs: 2.5mg once daily via nebulization; may increase to 2.5mg twice daily (see literature).
For patients <5yrs of age, use only if there is a potential for benefit in pulmonary function or in risk of respiratory tract infection. Use only with recommended nebulizers. Pregnancy (Cat.B). Nursing mothers.
Do not mix with other drugs in nebulizer.
Pharyngitis, voice alteration, laryngitis, rash, chest pain, conjunctivitis.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Adjunctive Therapies for Bipolar Disorder Show Promise, Need More Evidence
- Predicting Treatment-Emergent Mania to Tailor Pharmacotherapy in Bipolar Disorder
- Abnormalities of Cortical Thickness in Bipolar Disorder With Auditory Hallucinations
- Prevalence of ADHD Relatively Stable Over Time Despite Increase in Diagnoses
- Prevalence of Major Depressive Disorder Remains High In US Population
- The Way to the Head May Be Through the Gut: Probiotics for Depression
- Suicide-Screening Toolkit Can Help Identify Youths at High Risk for Suicide
- Agoraphobia: An Evolving Understanding of Definitions and Treatment
- Parental Pressure to Diet Linked With Long-term Harm in Adolescents
- Does Access to Medical Cannabis Reduce Risk for Opioid Abuse?
- Examining Rates of Long-term Opioid Use in Youth With Psychiatric Disorders
- Mortality Rates for Substance Use Disorders, Intentional Injuries Vary Widely By Country
- Facial Emotion Recognition Differentiates Behavioral Variant Frontotemporal Dementia From MDD
- The Challenge of Helping Uninsured Patients While Protecting Practice Finances
- Antidepressants Increase Seizure Risk in Youth and Severely Depressed